BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 12, 2025
Home » Newsletters » BioWorld

BioWorld

April 20, 2016

View Archived Issues

News from AACR

Kolltan Pharmaceuticals Inc., of New Haven, Conn., reported preclinical findings showing that an antibody-drug conjugate directed to the ALK receptor tyrosine kinase demonstrated efficacy in models of neuroblastoma. Read More

In the clinic

Boehringer Ingelheim GmbH, of Ingelheim, Germany. and Indianapolis-based Eli Lilly and Co. said they will conduct two outcome trials investigating the diabetes medicine Jardiance (empagliflozin) for the treatment of people with chronic heart failure. Read More

Other news to note

Spinalcyte LLC, of Houston, reported results from phase II animal studies testing human dermal fibroblasts (HDFs) for transplantation in intevertebral disc degeneration. Read More

Financings

Amryt Pharma plc, of Dublin, completed its £10 million (US$14.4 million) raise, placing about 41.7 million shares at 24 pence each, to fund accelerated development of Episalvan in epidermolysis bullosa. Read More

Regulatory front

Sri Krishna Pharmaceuticals Ltd., a contract manufacturing organization (CMO) based in Hyderabad, India, received a warning letter from the FDA about serious data violations. Read More

Seeking spark in Pfizer asset, Gemphire files for IPO alongside preclinical Phaserx

Gemphire Therapeutics Inc. and Phaserx Inc. have become the latest brave entrants to the biopharma IPO queue, joining 17 other contenders filed and pending, in a public financing climate significantly cooler than in 2015. Gemphire, a cardiovascular-focused clinical company with a midstage dyslipidemia drug, is seeking a proposed $60 million, while Phaserx, a preclinical company working on treatments for inherited enzyme deficiencies, has proposed raising up to $25.3 million. Read More

BBA formed to help U.K. catch up on biosimilars scene

LONDON – Biosimilars companies have joined forces to drive uptake of their products in the U.K., securing the backing of the National Health Service's (NHS) chief pharmaceutical officer in a push to promote competition against higher-price originators. Read More

Promethera eyes Canadian cell therapy filing post Cytonet deal

DUBLIN – Promethera Biosciences SA is acquiring the principal assets and expertise of Cytonet GmbH & Co KG in a stock-based deal that will combine two organizations focused on developing cell therapies for diseases of the liver. Read More

Eye-itch enrichment: NDA by Nicox for AC might win priority status via kid data

CEO Michele Garufi told BioWorld Today that Nicox SA's eye-drop form of cetirizine "has a good chance to take a nice market share" in eye itching related to allergic conjunctivitis (AC), and could win priority review, thanks to data in pediatric patients. "Of course, [market success] will depend on the partner that we select for commercialization," he added. Talks are under way. Read More

With $150M in the bank, Dalcor seeks phase III success with dalcetrapib

Seeking to succeed where big pharma failed, start-up Dalcor Pharma UK Ltd. completed a $100 million series B round to put an exclamation point on the $50 million series A the company closed late in 2015. Read More

Targeting the strong, silent type is challenging but not impossible

NEW ORLEANS – From a therapeutic point of view, having a bigger genomic mess is in some ways easier to deal with than a smaller one. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing